New Inteleos Features Gives Users the Ability to Tailor Information
New Inteleos Features Gives Users the Ability to Tailor Information
Amsterdam, December 6, 2006 – Elsevier, a world-leading healthcare and scientific publisher, announced today new features for its drug tracking and analysis tool, Inteleos. These features enable users to search drug records by Mechanism of Action and Drug Class, graphically chart competitor drugs using a new analysis tool, and search and review clinical trial reports from ClinicalTrials.gov. Users can increase productivity and improve results by specifically tailoring information to meet their business needs.
By indexing Mechanism of Action terms and creating a searchable Drug Class field, Inteleos increases the flexibility of its search and analysis features. The Competitive Grid analysis tool graphically charts competitor drugs per therapy area and allows for comparisons by mechanism of action or drug class, creating dynamic results instantly. Using information reported by ClinicalTrials.gov users can identify and analyze clinical trials across industry, government and academia. Users can also view key trial details specific to drug records.
"Our team continues to show real commitment to customer focus. Improvements made to Inteleos are based on industry feedback; users tell us what they need - the type of information and the format - to improve their business decision-making and we strive to meet these needs" says Julie Gordon, Director of Inteleos, Elsevier. "The inclusion of the Drug Class feature enhances the flexibility and breadth of searching and analysis possible and this is actualized by the Competitor Grid analysis tool. Trial information, via ClinicalTrials.gov, further expands our service into the clinical environment and is the starting point for future enhancements, as customers tell us this is an area of critical need."
In the coming months, Inteleos will enhance services for BizInt customers by enabling the export of Inteleos data into BizInt Smart Charts.
###
About InteleosInteleos provides business intelligence support to professionals working in or providing services to the pharmaceutical and biotech industries. Inteleos tracks drug development and associated licensing activities from late-stage preclinical through to launch and post-marketing studies. In addition to critical drug development information, Inteleos provides easy-to-use analysis tools to support decision-making and drive strategy. Inteleos is powered by AdvanTechnologies, Inc.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Media contact:
Heleen van Weel
The Reeves Agency
heleen@thereevesagency.com
Tel: +31 20 3051380
